Kol

Dubai-based Cryptocurrency Venture Capital 'Alpha Token Capital' Invests in $CVTX

Retrieved on: 
Tuesday, March 19, 2024
RPG, Web3, AMP, Kol, Partnership, Blockchain, MENA, Ecosystem, Cling, Multimedia, Marketing, Cryptocurrency

On the 15th, Carrieverse announced that it had entered into a strategic investment partnership with Dubai-based cryptocurrency venture capital firm Alpha Token Capital.

Key Points: 
  • On the 15th, Carrieverse announced that it had entered into a strategic investment partnership with Dubai-based cryptocurrency venture capital firm Alpha Token Capital.
  • Through this partnership, Alpha Token Capital will make a crypto investment in CVTX and a strategic investment in Carrieverse.
  • Alpha Token Capital is a global crypto venture capital firm with networks not only in Dubai but also in India and Singapore.
  • This investment is known to be Alpha Token Capital's first investment in a Korean token.

MarketAcross and Turingum Announce Strategic Partnership to Help Bridge the Japanese and Global Web3 Ecosystem

Retrieved on: 
Monday, September 25, 2023
Crypto.com, Crypto, Partnership, Marketing, Polygon, Kol, WJEK, Decentralized finance, SEO, EToro, Ecosystem, Environment, Cryptocurrency, Solana, Polka dot, PR

The partnership will help Japanese Web3 projects global, and the international projects seamlessly enter the Japanese market

Key Points: 
  • The partnership will help Japanese Web3 projects global, and the international projects seamlessly enter the Japanese market
    MarketAcross, the world’s leading blockchain PR & marketing firm, is delighted to announce that it has entered a strategic partnership with Turingum, a leading Japanese Web3 company focused on business consulting, tokenomics design, DeFi and smart contract development.
  • This partnership positions MarketAcross and Turingum to help the global Web3 projects expand into the Japanese market and vice versa, and seize the opportunities in the rapidly evolving crypto landscape.
  • Through MarketAcross, Turingum will secure a means to work with global companies and help expand opportunities for crypto projects seeking to enter the Japanese market.
  • MarketAcross is deeply connected to the Japanese Web3 ecosystem, working closely with the country’s No.1 public blockchain Astar Network.

MarketAcross and Chainlink Labs Establish Channel Partnership To Support Chainlink BUILD Members

Retrieved on: 
Wednesday, July 12, 2023
Crypto.com, Partnership, Marketing, Polygon, Kol, BUILD, SEO, EToro, Logic, Growth, Ecosystem, Cryptocurrency, Chain-link fencing, Binance, Solana, Polka dot, PR

MarketAcross , the world’s leading PR and content marketing solution for blockchain startups, today announced that it has entered into a channel partnership with Chainlink Labs, a developer of Chainlink , the industry-leading Web3 services platform.

Key Points: 
  • MarketAcross , the world’s leading PR and content marketing solution for blockchain startups, today announced that it has entered into a channel partnership with Chainlink Labs, a developer of Chainlink , the industry-leading Web3 services platform.
  • This channel partnership will help support startups in the Chainlink BUILD program and give them access to services in PR, content marketing, brand reputation, social promotions, influencer outreach (KoL), SEO, community growth, and more.
  • “We’re excited to partner with Chainlink Labs to help support Chainlink BUILD members with high-quality content marketing services.
  • “We’re thrilled to have MarketAcross support our Chainlink BUILD program as a channel partner.

VAPORESSO's New LUXE X Receives Positive Responses with Hundreds Lining up in UK and France

Retrieved on: 
Thursday, September 15, 2022
Cloud, Cornerstone, Thalia, Tottenham Court Road, Covent Garden, Thunder Force Gold Pack, Kol, Herbal cigarette, LUXE, Juice, ICE, Frucor Suntory, Technology, SSS, Multimedia, View, Oxford Street, Central London

SHENZHEN, China, Sept. 15, 2022 /PRNewswire/ --World-renowned vaping brand VAPORESSO has recently launched the all-new LUXE X pod to an overwhelmingly positive response from consumers.

Key Points: 
  • SHENZHEN, China, Sept. 15, 2022 /PRNewswire/ --World-renowned vaping brand VAPORESSO has recently launched the all-new LUXE X pod to an overwhelmingly positive response from consumers.
  • The all-new LUXE X from VAPORESSO is one of the brand's cornerstone flagship products as the first 40w pod system with non-replaceable coils.
  • Speaking to the launch of the LUXE X in the UK and France, VAPORESSO CMO, Thalia said, "We are excited to see that consumers are just as passionate about our new products as we are.
  • Extensive reviews of the LUXE X have also appeared on popular vaping media sites, who rated the LUXE X as one of the most flavorful pod vapes they've tried.

VAPORESSO's New LUXE X Receives Positive Responses with Hundreds Lining up in UK and France

Retrieved on: 
Thursday, September 15, 2022
Cloud, Cornerstone, Thalia, Tottenham Court Road, Covent Garden, Thunder Force Gold Pack, Kol, Herbal cigarette, LUXE, Juice, ICE, Frucor Suntory, Technology, SSS, Oxford Street, Central London

SHENZHEN, China, Sept. 15, 2022 /PRNewswire/ --World-renowned vaping brand VAPORESSO has recently launched the all-new LUXE X pod to an overwhelmingly positive response from consumers.

Key Points: 
  • SHENZHEN, China, Sept. 15, 2022 /PRNewswire/ --World-renowned vaping brand VAPORESSO has recently launched the all-new LUXE X pod to an overwhelmingly positive response from consumers.
  • The all-new LUXE X from VAPORESSO is one of the brand's cornerstone flagship products as the first 40w pod system with non-replaceable coils.
  • Speaking to the launch of the LUXE X in the UK and France, VAPORESSO CMO, Thalia said, "We are excited to see that consumers are just as passionate about our new products as we are.
  • Extensive reviews of the LUXE X have also appeared on popular vaping media sites, who rated the LUXE X as one of the most flavorful pod vapes they've tried.

Growing Social+NFT Industry Player 'Boom' Launches Bug-bounty Campaign

Retrieved on: 
Thursday, November 18, 2021
Internet, Non-fungible token, News, Telegraphy, Movement, UI, Suggestion, UX, Kol, USDT, Social media, NO, Social behavior, Life, Online shopping, Cryptocurrency, Lac, Risk management

As a decentralized Social+NFTplatform, Boom allows users to interact with and meaningfully support key opinion leaders around the world whilst earning rewards.

Key Points: 
  • As a decentralized Social+NFTplatform, Boom allows users to interact with and meaningfully support key opinion leaders around the world whilst earning rewards.
  • After receiving a lot of hype recently, people have started to pick apart what the 'metaverse' will actually be.
  • As, As social animals, we all share a desire to be a part of a community and seek meaningful engagements with one another.
  • Aside from a growing community, there is much, much more rich functionality to come, with Boom set to be the next biggest thing in the decentralized revolution.

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Retrieved on: 
Thursday, August 5, 2021
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Roche, APL, Venetoclax, Gene, Safety, LinkedIn, Clinical trial, MDS, Compte rendu, Acute myeloid leukemia, Annual report, Acute promyelocytic leukemia, Twitter, CDK, ESMO, ID, Immunotherapy, Research, Genome, G&A, Lists of people executed in the United States, Security (finance), Lung, Investor, BRAF, Azacitidine, Congress, Fulvestrant, Workforce, Cyclin-dependent kinase 7, Rara, Breast, Arsenic trioxide, Initiate, Nasdaq, U.S. Securities and Exchange Commission, Webcast, Freedom, GBT, Private Securities Litigation Reform Act, Kol, Hematology, Government, AML, Selective estrogen receptor degrader, Patient, COVID-19, Ovarian cancer, Colorectal cancer, Phase 1, Histology, Pharmaceutical industry, Medical device

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.
  • Research and development expenses were $25.8 million for the first quarter of 2021, as compared to $14.8 million for the second quarter of 2020.
  • General and administrative (G&A) expenses were $5.5 million for the second quarter of 2021, as compared to $5.1 million for the second quarter of 2020.
  • ET to discuss these second quarter 2021 financial results and provide a corporate update.

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Retrieved on: 
Thursday, August 5, 2021
Pharmaceutical, Health, Practice Management, Cardiology, Heart failure with preserved ejection fraction, Johns Hopkins Hospital, Education, Medical director, Heart failure, Tenax, Hemodynamics, City, Eastern Time Zone, Columbia University, Private Securities Litigation Reform Act, Pulmonary hypertension, CRF, Q&A, Johns Hopkins School of Medicine, Heart Failure Society of America, Therapy, Security (finance), World Health Organization, BCR, Population, Orion Corporation, Annual report, SEC, Exercise, Form 10-K, Compliance, Company, Research, U.S. Securities and Exchange Commission, Webcast, Trial of the century, Kol, Philosophy, Form, Patient, Imatinib, News, Acute leukemia, Nasdaq, Stomach, Goal, Platelet-derived growth factor, Pharmaceutical industry, Tenax Therapeutics, Levosimendan, Imatinib, TENAX THERAPEUTICS, LEVOSIMENDAN, IMATINIB

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that it will hold a KOL webinar on Levosimendan for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

Key Points: 
  • Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that it will hold a KOL webinar on Levosimendan for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
  • The Company owns North American rights to develop and commercialize levosimendan and has recently released detailed results from the Phase 2 HELP Study of levosimendan in Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting.
  • It initially was developed as an inotrope for intravenous use in hospitalized patients with acutely decompensated heart failure.
  • The inhibitory effects of imatinib on PDGF receptors and c-KIT suggested that it may be efficacious in Pulmonary Arterial Hypertension.

Acceleration Point Provides Medical Key Opinion Leader (KOL) Social Media Monitoring Platform

Retrieved on: 
Tuesday, June 15, 2021
Other Health, Other Science, Other Professional Services, Pharmaceutical, Other Technology, Research, Software, Consulting, Data management, Professional services, Science, Social media, Technology, Other Communications, General Health, Biotechnology, Health, Communications, Contents, Media monitoring, Social media, Social media measurement, Kol, Consultant, Collaboration, Mass media, Medical science liaison

Acceleration Point , a Medical Affairs consulting firm that helps clients improve the execution of Medical Affairs strategies, today announced the launch of its enhanced Key Opinion Leader (KOL) Social Media Monitoring Platform.

Key Points: 
  • Acceleration Point , a Medical Affairs consulting firm that helps clients improve the execution of Medical Affairs strategies, today announced the launch of its enhanced Key Opinion Leader (KOL) Social Media Monitoring Platform.
  • The KOL Social Media Monitoring Platform is built and customized specifically for Medical Affairs teams in the pharmaceutical industry.
  • The platform offers insights and engagement opportunities with existing KOLs and new Digital Key Opinion Leaders (DKOLs) in one comprehensive platform.
  • As Medical Affairs teams explore scientific social networks, Acceleration Points platform saves them time and provides deeper insights by providing a complete follower analysis.

Skylight Health to Host Virtual KOL Event Focusing on the US Healthcare Market

Retrieved on: 
Wednesday, February 24, 2021
Cisco Webex, Remote administration software, Videotelephony, Web conferencing, OTC Markets Group, Healthcare industry, Kol, Software, Companies, Computing

TORONTO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (Skylight Health or the Company), one of the largest multi-specialty healthcare systems in the United States, today announced that they will host a virtual Key Opinion Leader (KOL) event on the Future of Healthcare in the US.

Key Points: 
  • TORONTO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (Skylight Health or the Company), one of the largest multi-specialty healthcare systems in the United States, today announced that they will host a virtual Key Opinion Leader (KOL) event on the Future of Healthcare in the US.
  • The Skylight Health Virtual KOL Event details as follows:
    To join the meeting using Webex, click the link here .
  • Skylight Health hosted a Special Meeting of Shareholders on Monday, February 22, 2021.
  • Skylight Health Group (TSXV:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes.